The Tranexaminic acid - Aprotinin - Placebo trial.
Completed
- Conditions
- Intra-operative medication trial.
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Patients scheduled for first time, non-complex (one or two procedures) open heart surgery with the use of CPB.
Exclusion Criteria
1. Less than 18 years old;
2. Previous sternotomy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Intraoperative and perioperative blood loss;<br /><br>2. Intraoperative and perioperative use of blood products.
- Secondary Outcome Measures
Name Time Method 1. Rethoracotomies;<br /><br>2. The total duration of each patient's stay in the operating room;<br /><br>3. Length of stay in the ICU and hospital;<br /><br>4. Development of SIRS/sepsis/MOF;<br /><br>5. 30-day morbidity;<br /><br>6. 30-day mortality;<br /><br>7. Costs.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aprotinin and tranexamic acid's antifibrinolytic effects in cardiac surgery?
How does high-dose aprotinin compare to tranexamic acid in reducing perioperative blood loss in first-time open-heart surgery patients?
Are there specific biomarkers that predict response to antifibrinolytic agents in cardiac surgical settings?
What are the potential adverse events associated with high-dose aprotinin use in cardiac surgery and how are they managed?
What alternative antifibrinolytic drugs or combination therapies are being evaluated for efficacy in open-heart surgery compared to aprotinin and tranexamic acid?